Neurology Clinical Trials Market

Neurology Clinical Trials Market Size and Share Forecast Outlook from 2022 to 2032

The global Neurology Clinical Trials Market was valued at around USD 5.4 billion in 2021.

With a projected CAGR of 6.3% for the next ten years, the market is likely to reach a valuation of nearly USD 10.5 billion by the end of 2032. The neurology clinical trials market is expected to achieve an absolute dollar opportunity growth of USD 4.8 billion over the forecasted period.

Attributes	Details
Neurology Clinical Trials Market Size (2021A)	USD 5.4 billion
Neurology Clinical Trials Market Size (2022E)	USD 5.7 billion
Projected Market Value (2032F)	USD 10.5 billion
Global Market Growth Rate (2022 to 2032)	6.3% CAGR
Key Companies Profiled	IQVIA; Novartis; Covance; Medpace; Charles River Laboratories; GlaxoSmithKline; Aurora Healthcare; Biogen

Comparison of Historical vs Future Trends in Neurology Clinical Trials Market

Future Market Insights reveals that Interventional study design led the market for neurology clinical trials. Market revenue through interventional study design grew at 5.6% CAGR from 2017 to 2021. While Huntington’s disease maintained the top Indication in neurology, clinical trials with a growth rate of 5.2% from 2017 to 2021.

The market is likely to grow due to an increase in global neurological disorders. This will drive the market for government spending and collaboration from pharmaceutical companies for the collaboration of new drugs and medication.

According to Lancet medical journal, total disability life adjusted years (DALYs) from, non-communicable neurological disorders like stroke, Alzheimer’s disease, dementia, Parkinson’s disease, and headache disorders increased in India and contributed 82.8% in 2019. Neurological disorders like stroke contributed to the highest share of deaths in India followed by Alzheimer’s.

Based on the study, changes in lifestyle habits were a substantial contributor to non-communicable diseases. For instance, high systolic blood pressure, air pollution, and dietary factor contributed to 55.3%, 42.2%, and 28.1% respectively strokes.

Top Neurology Clinical Trials Market Barriers and Strategic Challenges

The requirement for neurology clinical trials is soaring, but several pharmaceutical companies are leaving the market due to the high cost of clinical trials across therapeutic areas and the high failure rates of clinical trials.

Based on the Tufts Center for the Study of Drug Development, CNS drugs take 18% more time to develop when compared to other drugs, and only 6% of drugs are finally approved out of clinical testing. These statistics are discouraging enough for pharmaceutical companies not to invest in neurological clinical trials.

In order to make the transition from Phase I to Phase II trial, companies require data packages to enhance upcoming investments. Few academic and market scientists refuse to share data resulting in a delay in clinical trials.

On the other hand, diagnosis of the central nervous system (CNS) is studied on the basis of symptoms, and signs, and the reasons are varied in different patients within existing diagnostic categories. This makes the identification of the problem difficult.

Moreover, animal models have not shown effective predictive validity and reproducibility. Animal models of CNS disorders are less understood and are not able to recreate the varied neurological human disorders on their model.

Investment Trends and Strategic Opportunities in Early vs Late Stage Neurology Clinical Trials

With the rise in neurological diseases, such as Alzheimer’s disease and Huntington's disease neuroscience remains a key domain for the majority of investments due to the high societal and monetary burden. Pharma and medical device companies have joined hands to offer better understanding and improved treatment.

Moreover, the unprecedented rise in neurological disorders has called for the government to support funding for neurology clinical trials.

Scientists at the University of Sheffield’s Neuroscience Institute and NIHR Sheffield Biomedical Research Centre received funding of USD 61 Million from the government to bring suitable treatment options for motor neuron disease (MillionD). The funding is expected to change the clinical trials in the coming years.

The government of Australia invested USD 21.8 Million for the treatment of varied neurological disorders. Around 10 research projects were earmarked in Australia for the treatment of Supranuclear palsy and attempts would be made to reduce fatigue in patients after a stroke.

Furthermore, the Clinical Trials Activity Initiative by the Australian Government aims to provide USD 750 Million over 10 years from 2022 to 23 to Australian researchers in order to increase clinical trials in the country.

Overview of Neurology Clinical Trials Market by Region

How is the market for neurology clinical trials shaping up in Europe?

The total number of DALYs resulting from neurological disorders was 21 million in the European Union, in 2017 and 41.1 million in WHO European region. A substantial burden will likely catch the attention of neurological clinical trials in Europe.

Development in the healthcare system has extended life expectancy. An increase in the older population has also come up with the burden of non-communicable neurological diseases which is the main driver for spending in neurology clinical trials in Europe.

Analysis of Leading Countries in Neurology Clinical Trials: Development and Execution

The USA Neurology Clinical Trials Market Analysis

The market for neurology clinical trials in the USA is valued at USAD 3.7 billion by 2032. Revenue through neurology clinical trials grew at 5.3% CAGR from 2017 to 2021. The USA contributes to a vast number of neurological patients which drives the need for expanding clinical trials. In 2020, 5.8 million Americans suffered from Alzheimer’s disease. This number is projected to triple to 14 million by 2060.

Companies like Biogen and IQVIA have continuously advanced in innovating new drugs and receiving FDA approvals for neurological disorders in America. Government agencies like the National Institute of Neurological Disorders and Stroke fund clinical trials and numerous research programs to reduce the burden of neurological disorders in the USA. The absolute dollar opportunity growth in the USA is expected to be at USAD 1.8 billion during the forecasted period of 2022 to 2032.

United Kingdom Neurology Clinical Trials Market Analysis

The market for neurology clinical trials in the United Kingdom was valued at USAD 226 million in 2021. With an absolute dollar opportunity of USAD 254 million, the market in the country is projected to reach a valuation of USAD 493 million by 2032. From 2022 to 2032, the market in the United Kingdom is projected to grow at a CAGR of 7.6%.

Japan Neurology Clinical Trials Market Analysis

In Japan, the neurology clinical trials market in Japan was held at USAD 179 million in 2021. By 2032, the market in Japan is expected to reach a valuation of USAD 338 million. Growing at a CAGR of 5.7% from 2022 to 2032, the market in the country is likely to gross an absolute dollar opportunity of USAD 145 million.

South Korea Neurology Clinical Trials Market Analysis

The neurology clinical trials market in South Korea is expected to be valued at USAD 192 million by 2032. With a CAGR of 5.9%, the market in South Korea is expected to gross an absolute dollar opportunity of USAD 84 million during the forecast period.

Neurology Clinical Trials Market Breakdown by Trial Phase, Indication, and Type

How has the market for neurology clinical trials influenced study design methods?

Interventional study design dominated the market for neurology clinical trials and accounted for a 5.6% CAGR from 2017 to 2021. It is expected to grow at a rate of 6.5% during the forecasted period.

The interventional study design is preferable in most clinical trials due to its safety and cost-effectiveness and acceptability of the Intervention. Interventional study design assists in gauging the direct impact on treatments or prevention of neurological diseases.

Key Neurology Clinical Trials Market Players and Competitive Strategies

Health organizations and pharmaceutical companies are largely aiming at expanding their manufacturing facilities, investing in Research and Development (R&D), and inventing new drugs for the treatment of neurological disorders.

The key companies operating in the neurology clinical trials market include Novartis, Covance, Medpace, Charles River Laboratories, Syneous Health, Icon Plc, GlaxoSmithKline, Aurora Healthcare, Biogen, and IQVIA.

Some of the recent developments by key providers of neurology clinical trials are as follows:

• In June 2022, Novartis announced the publication of Nature Medicine of Zolgensma data. The data revealed that children with spinal muscular atrophy (SMA) treated with Zolgensma were able to retain age-appropriate motor skills such as sitting, standing, and walking independently.
• In June 2022, Biogen joined hands with Alectos Therapeutics to develop and commercialize a small molecule therapy known as AL01811, as a possible treatment for Parkinson’s disease. The collaboration will benefit Alectos with USD 77.5 and USD 630 million for development and commercial payments respectively. Moreover, Biogen will conduct responsible for regulatory costs and manufacturing once the therapy is approved for clinical settings.
• In June 2022, Scientists at Yale University discovered that a drug developed by Bristol Myers Squibb has the ability to repair the loss of neuronal nexus known as synapse which is the key contributor to cognitive decline. The study also stated that it has the ability to restore synaptic connections in Alzheimer’s mouse models. The drug also minimized the toxic build-up of tau protein present in the brain of animals.
• In April 2022, Novartis announced long-term data of Phase 3 ASCLEPIOS I/II trials. The data exhibited the efficacy of Kesimpta and stated that treatment of four years will reduce the risk of three and six months of confirmed disability and fewer relapses.
• In April 2022, FDA granted Novartis, a commercial license to manufacture Zolgensma, a multi-product gene therapy with a 170,000 square-foot facility at Durham, N.C. site to test and release Zolgensma.
• In December 2021, Novartis paid UCB USD 150 million to provide the development of drugs relating to two clinical-stage Parkinson’s diseases. With the partnership with UCB, Novartis aims to widen its neuroscience prospectus. Based on their terms of collaboration, both the company intended to co-developing and fund the drug and further share the costs of additional development of the drug.
• In July 2021, GlaxoSmithKline and Alector collaborated for two clinical-stage progranulin-elevating monoclonal antibodies, AL001 and AL101 for neurodegenerative diseases such as dementia, Parkinson’s disease, and Alzheimer’s disease.

Similarly, recent developments related to companies involved in Neurology Clinical Trials have been tracked by the team at Future Market Insights, which is available in the full report.

Table of Content

• 1. Executive Summary 
• 2. Market Overview
• 3. Market Background
• 4. Global Market Analysis 2017 to 2021 and Forecast, 2022 to 2032
• 5. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Phase
  • 5.1. Phase I
  • 5.2. Phase II
  • 5.3. Phase III
  • 5.4. Phase IV
• 6. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Study Design
  • 6.1. Interventional
  • 6.2. Observational
  • 6.3. Expanded Access
• 7. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Indication
  • 7.1. Epilepsy
  • 7.2. Parkinson's Disease (PD)
  • 7.3. Huntington's Disease
  • 7.4. Stroke
  • 7.5. Traumatic Brain Injury (TBI)
  • 7.6. Amyotrophic Lateral Sclerosis (ALS)
  • 7.7. Muscle regeneration
  • 7.8. Other Indications
• 8. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region
  • 8.1. North America
  • 8.2. Latin America
  • 8.3. Europe
  • 8.4. East Asia
  • 8.5. South Asia
  • 8.6. Oceania
  • 8.7. Middle East and Africa (MEA)
• 9. North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
• 10. Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
• 11. Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
• 12. East Asia Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
• 13. South Asia Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
• 14. Oceania Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
• 15. MEA Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
• 16. Key Countries Market Analysis
• 17. Market Structure Analysis
• 18. Competition Analysis
  • 18.1. IQVIA
  • 18.2. Novartis
  • 18.3. Covance
  • 18.4. Medpace
  • 18.5. Charles River Laboratories
  • 18.6. GlaxoSmithKline
  • 18.7. Aurora Healthcare
  • 18.8. Biogen
• 19. Assumptions & Acronyms Used
• 20. Research Methodology

List of Tables

Table 1: Global Market Value (US$ Million) Forecast by Region, 2017 to 2032

Table 2: Global Market Value (US$ Million) Forecast by Phase, 2017 to 2032

Table 3: Global Market Value (US$ Million) Forecast by Study Design, 2017 to 2032

Table 4: Global Market Value (US$ Million) Forecast by Indication, 2017 to 2032

Table 5: North America Market Value (US$ Million) Forecast by Country, 2017 to 2032

Table 6: North America Market Value (US$ Million) Forecast by Phase, 2017 to 2032

Table 7: North America Market Value (US$ Million) Forecast by Study Design, 2017 to 2032

Table 8: North America Market Value (US$ Million) Forecast by Indication, 2017 to 2032

Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2017 to 2032

Table 10: Latin America Market Value (US$ Million) Forecast by Phase, 2017 to 2032

Table 11: Latin America Market Value (US$ Million) Forecast by Study Design, 2017 to 2032

Table 12: Latin America Market Value (US$ Million) Forecast by Indication, 2017 to 2032

Table 13: Europe Market Value (US$ Million) Forecast by Country, 2017 to 2032

Table 14: Europe Market Value (US$ Million) Forecast by Phase, 2017 to 2032

Table 15: Europe Market Value (US$ Million) Forecast by Study Design, 2017 to 2032

Table 16: Europe Market Value (US$ Million) Forecast by Indication, 2017 to 2032

Table 17: East Asia Market Value (US$ Million) Forecast by Country, 2017 to 2032

Table 18: East Asia Market Value (US$ Million) Forecast by Phase, 2017 to 2032

Table 19: East Asia Market Value (US$ Million) Forecast by Study Design, 2017 to 2032

Table 20: East Asia Market Value (US$ Million) Forecast by Indication, 2017 to 2032

Table 21: South Asia Market Value (US$ Million) Forecast by Country, 2017 to 2032

Table 22: South Asia Market Value (US$ Million) Forecast by Phase, 2017 to 2032

Table 23: South Asia Market Value (US$ Million) Forecast by Study Design, 2017 to 2032

Table 24: South Asia Market Value (US$ Million) Forecast by Indication, 2017 to 2032

Table 25: Oceania Market Value (US$ Million) Forecast by Country, 2017 to 2032

Table 26: Oceania Market Value (US$ Million) Forecast by Phase, 2017 to 2032

Table 27: Oceania Market Value (US$ Million) Forecast by Study Design, 2017 to 2032

Table 28: Oceania Market Value (US$ Million) Forecast by Indication, 2017 to 2032

Table 29: MEA Market Value (US$ Million) Forecast by Country, 2017 to 2032

Table 30: MEA Market Value (US$ Million) Forecast by Phase, 2017 to 2032

Table 31: MEA Market Value (US$ Million) Forecast by Study Design, 2017 to 2032

Table 32: MEA Market Value (US$ Million) Forecast by Indication, 2017 to 2032

List of Figures

Figure 1: Global Market Value (US$ million) by Phase, 2022 to 2032

Figure 2: Global Market Value (US$ million) by Study Design, 2022 to 2032

Figure 3: Global Market Value (US$ million) by Indication, 2022 to 2032

Figure 4: Global Market Value (US$ million) by Region, 2022 to 2032

Figure 5: Global Market Value (US$ million) Analysis by Region, 2017 to 2032

Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2022 to 2032

Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2022 to 2032

Figure 8: Global Market Value (US$ million) Analysis by Phase, 2017 to 2032

Figure 9: Global Market Value Share (%) and BPS Analysis by Phase, 2022 to 2032

Figure 10: Global Market Y-o-Y Growth (%) Projections by Phase, 2022 to 2032

Figure 11: Global Market Value (US$ million) Analysis by Study Design, 2017 to 2032

Figure 12: Global Market Value Share (%) and BPS Analysis by Study Design, 2022 to 2032

Figure 13: Global Market Y-o-Y Growth (%) Projections by Study Design, 2022 to 2032

Figure 14: Global Market Value (US$ million) Analysis by Indication, 2017 to 2032

Figure 15: Global Market Value Share (%) and BPS Analysis by Indication, 2022 to 2032

Figure 16: Global Market Y-o-Y Growth (%) Projections by Indication, 2022 to 2032

Figure 17: Global Market Attractiveness by Phase, 2022 to 2032

Figure 18: Global Market Attractiveness by Study Design, 2022 to 2032

Figure 19: Global Market Attractiveness by Indication, 2022 to 2032

Figure 20: Global Market Attractiveness by Region, 2022 to 2032

Figure 21: North America Market Value (US$ million) by Phase, 2022 to 2032

Figure 22: North America Market Value (US$ million) by Study Design, 2022 to 2032

Figure 23: North America Market Value (US$ million) by Indication, 2022 to 2032

Figure 24: North America Market Value (US$ million) by Country, 2022 to 2032

Figure 25: North America Market Value (US$ million) Analysis by Country, 2017 to 2032

Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2022 to 2032

Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032

Figure 28: North America Market Value (US$ million) Analysis by Phase, 2017 to 2032

Figure 29: North America Market Value Share (%) and BPS Analysis by Phase, 2022 to 2032

Figure 30: North America Market Y-o-Y Growth (%) Projections by Phase, 2022 to 2032

Figure 31: North America Market Value (US$ million) Analysis by Study Design, 2017 to 2032

Figure 32: North America Market Value Share (%) and BPS Analysis by Study Design, 2022 to 2032

Figure 33: North America Market Y-o-Y Growth (%) Projections by Study Design, 2022 to 2032

Figure 34: North America Market Value (US$ million) Analysis by Indication, 2017 to 2032

Figure 35: North America Market Value Share (%) and BPS Analysis by Indication, 2022 to 2032

Figure 36: North America Market Y-o-Y Growth (%) Projections by Indication, 2022 to 2032

Figure 37: North America Market Attractiveness by Phase, 2022 to 2032

Figure 38: North America Market Attractiveness by Study Design, 2022 to 2032

Figure 39: North America Market Attractiveness by Indication, 2022 to 2032

Figure 40: North America Market Attractiveness by Country, 2022 to 2032

Figure 41: Latin America Market Value (US$ million) by Phase, 2022 to 2032

Figure 42: Latin America Market Value (US$ million) by Study Design, 2022 to 2032

Figure 43: Latin America Market Value (US$ million) by Indication, 2022 to 2032

Figure 44: Latin America Market Value (US$ million) by Country, 2022 to 2032

Figure 45: Latin America Market Value (US$ million) Analysis by Country, 2017 to 2032

Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2022 to 2032

Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032

Figure 48: Latin America Market Value (US$ million) Analysis by Phase, 2017 to 2032

Figure 49: Latin America Market Value Share (%) and BPS Analysis by Phase, 2022 to 2032

Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Phase, 2022 to 2032

Figure 51: Latin America Market Value (US$ million) Analysis by Study Design, 2017 to 2032

Figure 52: Latin America Market Value Share (%) and BPS Analysis by Study Design, 2022 to 2032

Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Study Design, 2022 to 2032

Figure 54: Latin America Market Value (US$ million) Analysis by Indication, 2017 to 2032

Figure 55: Latin America Market Value Share (%) and BPS Analysis by Indication, 2022 to 2032

Figure 56: Latin America Market Y-o-Y Growth (%) Projections by Indication, 2022 to 2032

Figure 57: Latin America Market Attractiveness by Phase, 2022 to 2032

Figure 58: Latin America Market Attractiveness by Study Design, 2022 to 2032

Figure 59: Latin America Market Attractiveness by Indication, 2022 to 2032

Figure 60: Latin America Market Attractiveness by Country, 2022 to 2032

Figure 61: Europe Market Value (US$ million) by Phase, 2022 to 2032

Figure 62: Europe Market Value (US$ million) by Study Design, 2022 to 2032

Figure 63: Europe Market Value (US$ million) by Indication, 2022 to 2032

Figure 64: Europe Market Value (US$ million) by Country, 2022 to 2032

Figure 65: Europe Market Value (US$ million) Analysis by Country, 2017 to 2032

Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2022 to 2032

Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032

Figure 68: Europe Market Value (US$ million) Analysis by Phase, 2017 to 2032

Figure 69: Europe Market Value Share (%) and BPS Analysis by Phase, 2022 to 2032

Figure 70: Europe Market Y-o-Y Growth (%) Projections by Phase, 2022 to 2032

Figure 71: Europe Market Value (US$ million) Analysis by Study Design, 2017 to 2032

Figure 72: Europe Market Value Share (%) and BPS Analysis by Study Design, 2022 to 2032

Figure 73: Europe Market Y-o-Y Growth (%) Projections by Study Design, 2022 to 2032

Figure 74: Europe Market Value (US$ million) Analysis by Indication, 2017 to 2032

Figure 75: Europe Market Value Share (%) and BPS Analysis by Indication, 2022 to 2032

Figure 76: Europe Market Y-o-Y Growth (%) Projections by Indication, 2022 to 2032

Figure 77: Europe Market Attractiveness by Phase, 2022 to 2032

Figure 78: Europe Market Attractiveness by Study Design, 2022 to 2032

Figure 79: Europe Market Attractiveness by Indication, 2022 to 2032

Figure 80: Europe Market Attractiveness by Country, 2022 to 2032

Figure 81: East Asia Market Value (US$ million) by Phase, 2022 to 2032

Figure 82: East Asia Market Value (US$ million) by Study Design, 2022 to 2032

Figure 83: East Asia Market Value (US$ million) by Indication, 2022 to 2032

Figure 84: East Asia Market Value (US$ million) by Country, 2022 to 2032

Figure 85: East Asia Market Value (US$ million) Analysis by Country, 2017 to 2032

Figure 86: East Asia Market Value Share (%) and BPS Analysis by Country, 2022 to 2032

Figure 87: East Asia Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032

Figure 88: East Asia Market Value (US$ million) Analysis by Phase, 2017 to 2032

Figure 89: East Asia Market Value Share (%) and BPS Analysis by Phase, 2022 to 2032

Figure 90: East Asia Market Y-o-Y Growth (%) Projections by Phase, 2022 to 2032

Figure 91: East Asia Market Value (US$ million) Analysis by Study Design, 2017 to 2032

Figure 92: East Asia Market Value Share (%) and BPS Analysis by Study Design, 2022 to 2032

Figure 93: East Asia Market Y-o-Y Growth (%) Projections by Study Design, 2022 to 2032

Figure 94: East Asia Market Value (US$ million) Analysis by Indication, 2017 to 2032

Figure 95: East Asia Market Value Share (%) and BPS Analysis by Indication, 2022 to 2032

Figure 96: East Asia Market Y-o-Y Growth (%) Projections by Indication, 2022 to 2032

Figure 97: East Asia Market Attractiveness by Phase, 2022 to 2032

Figure 98: East Asia Market Attractiveness by Study Design, 2022 to 2032

Figure 99: East Asia Market Attractiveness by Indication, 2022 to 2032

Figure 100: East Asia Market Attractiveness by Country, 2022 to 2032

Figure 101: South Asia Market Value (US$ million) by Phase, 2022 to 2032

Figure 102: South Asia Market Value (US$ million) by Study Design, 2022 to 2032

Figure 103: South Asia Market Value (US$ million) by Indication, 2022 to 2032

Figure 104: South Asia Market Value (US$ million) by Country, 2022 to 2032

Figure 105: South Asia Market Value (US$ million) Analysis by Country, 2017 to 2032

Figure 106: South Asia Market Value Share (%) and BPS Analysis by Country, 2022 to 2032

Figure 107: South Asia Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032

Figure 108: South Asia Market Value (US$ million) Analysis by Phase, 2017 to 2032

Figure 109: South Asia Market Value Share (%) and BPS Analysis by Phase, 2022 to 2032

Figure 110: South Asia Market Y-o-Y Growth (%) Projections by Phase, 2022 to 2032

Figure 111: South Asia Market Value (US$ million) Analysis by Study Design, 2017 to 2032

Figure 112: South Asia Market Value Share (%) and BPS Analysis by Study Design, 2022 to 2032

Figure 113: South Asia Market Y-o-Y Growth (%) Projections by Study Design, 2022 to 2032

Figure 114: South Asia Market Value (US$ million) Analysis by Indication, 2017 to 2032

Figure 115: South Asia Market Value Share (%) and BPS Analysis by Indication, 2022 to 2032

Figure 116: South Asia Market Y-o-Y Growth (%) Projections by Indication, 2022 to 2032

Figure 117: South Asia Market Attractiveness by Phase, 2022 to 2032

Figure 118: South Asia Market Attractiveness by Study Design, 2022 to 2032

Figure 119: South Asia Market Attractiveness by Indication, 2022 to 2032

Figure 120: South Asia Market Attractiveness by Country, 2022 to 2032

Figure 121: Oceania Market Value (US$ million) by Phase, 2022 to 2032

Figure 122: Oceania Market Value (US$ million) by Study Design, 2022 to 2032

Figure 123: Oceania Market Value (US$ million) by Indication, 2022 to 2032

Figure 124: Oceania Market Value (US$ million) by Country, 2022 to 2032

Figure 125: Oceania Market Value (US$ million) Analysis by Country, 2017 to 2032

Figure 126: Oceania Market Value Share (%) and BPS Analysis by Country, 2022 to 2032

Figure 127: Oceania Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032

Figure 128: Oceania Market Value (US$ million) Analysis by Phase, 2017 to 2032

Figure 129: Oceania Market Value Share (%) and BPS Analysis by Phase, 2022 to 2032

Figure 130: Oceania Market Y-o-Y Growth (%) Projections by Phase, 2022 to 2032

Figure 131: Oceania Market Value (US$ million) Analysis by Study Design, 2017 to 2032

Figure 132: Oceania Market Value Share (%) and BPS Analysis by Study Design, 2022 to 2032

Figure 133: Oceania Market Y-o-Y Growth (%) Projections by Study Design, 2022 to 2032

Figure 134: Oceania Market Value (US$ million) Analysis by Indication, 2017 to 2032

Figure 135: Oceania Market Value Share (%) and BPS Analysis by Indication, 2022 to 2032

Figure 136: Oceania Market Y-o-Y Growth (%) Projections by Indication, 2022 to 2032

Figure 137: Oceania Market Attractiveness by Phase, 2022 to 2032

Figure 138: Oceania Market Attractiveness by Study Design, 2022 to 2032

Figure 139: Oceania Market Attractiveness by Indication, 2022 to 2032

Figure 140: Oceania Market Attractiveness by Country, 2022 to 2032

Figure 141: MEA Market Value (US$ million) by Phase, 2022 to 2032

Figure 142: MEA Market Value (US$ million) by Study Design, 2022 to 2032

Figure 143: MEA Market Value (US$ million) by Indication, 2022 to 2032

Figure 144: MEA Market Value (US$ million) by Country, 2022 to 2032

Figure 145: MEA Market Value (US$ million) Analysis by Country, 2017 to 2032

Figure 146: MEA Market Value Share (%) and BPS Analysis by Country, 2022 to 2032

Figure 147: MEA Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032

Figure 148: MEA Market Value (US$ million) Analysis by Phase, 2017 to 2032

Figure 149: MEA Market Value Share (%) and BPS Analysis by Phase, 2022 to 2032

Figure 150: MEA Market Y-o-Y Growth (%) Projections by Phase, 2022 to 2032

Figure 151: MEA Market Value (US$ million) Analysis by Study Design, 2017 to 2032

Figure 152: MEA Market Value Share (%) and BPS Analysis by Study Design, 2022 to 2032

Figure 153: MEA Market Y-o-Y Growth (%) Projections by Study Design, 2022 to 2032

Figure 154: MEA Market Value (US$ million) Analysis by Indication, 2017 to 2032

Figure 155: MEA Market Value Share (%) and BPS Analysis by Indication, 2022 to 2032

Figure 156: MEA Market Y-o-Y Growth (%) Projections by Indication, 2022 to 2032

Figure 157: MEA Market Attractiveness by Phase, 2022 to 2032

Figure 158: MEA Market Attractiveness by Study Design, 2022 to 2032

Figure 159: MEA Market Attractiveness by Indication, 2022 to 2032

Figure 160: MEA Market Attractiveness by Country, 2022 to 2032